Literature DB >> 22591

The pharmacologic effects of furosemide therapy in the low-birth-weight infant.

B S Ross, A Pollak, W Oh.   

Abstract

The pharmacologic effects of furosemide were studied in six infants (mean gestation 30.7 weeks; mean birth weight 1,490 gm) at ages 10 to 57 days. Furosemide (for clinical indication, standardized at 1 mg/kg) was given intravenously over one minute; data were collected over the ensuing 24 hours. For three hours following furosemide administration, a significant diuresis was observed. Sodium excretion, percent fractional sodium excretion, and potassium excretion were significantly increased and urinary pH significantly decreased for six hours following the administration of furosemide. Creatinine and free water clearances were slightly elevated, although not significantly. Furosemide is an effective diuretic, the onset of pharmacologic action was within one hour, the peak action was sustained for three hours, and the duration of action was six hours. The net fluid, sodium, and potassium losses following a 1 mg/kg single dose were 28 ml, and 3.6 and 0.3 mEq/kg, respectively.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 22591     DOI: 10.1016/s0022-3476(78)80098-5

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

1.  Ultrasound diagnosis of nephrocalcinosis in preterm infants.

Authors:  N Woolfield; R Haslam; G Le Quesne; H M Chambers; R Hogg; K Jureidini
Journal:  Arch Dis Child       Date:  1988-01       Impact factor: 3.791

Review 2.  Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants.

Authors:  Gian Maria Pacifici
Journal:  Paediatr Drugs       Date:  2012-08-01       Impact factor: 3.022

3.  Pharmacokinetics of furosemide in neonates.

Authors:  P Vert; M Broquaire; M Legagneur; P L Morselli
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

4.  The association between diuretic class exposures and enteral electrolyte use in infants developing grade 2 or 3 bronchopulmonary dysplasia in United States children's hospitals.

Authors:  Timothy D Nelin; Scott Lorch; Erik A Jensen; Stamatia Alexiou; Kathleen Gibbs; Natalie Napolitano; Heather M Monk; Susan Furth; Justine Shults; Nicolas A Bamat
Journal:  J Perinatol       Date:  2021-01-28       Impact factor: 2.521

Review 5.  Urolithiasis in children: current medical management.

Authors:  J Laufer; H Boichis
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

6.  Determinants of the diuretic response to furosemide in infants with congestive heart failure.

Authors:  T P Green; B L Mirkin
Journal:  Pediatr Cardiol       Date:  1982       Impact factor: 1.655

7.  Renal response to frusemide in preterm infants with respiratory distress syndrome during the first three postnatal days.

Authors:  T F Yeh; D Raval; E John; R S Pildes
Journal:  Arch Dis Child       Date:  1985-07       Impact factor: 3.791

8.  Pharmacokinetics of diuretics and methylxanthines in the neonate.

Authors:  J V Aranda; T Turmen; B I Sasyniuk
Journal:  Eur J Clin Pharmacol       Date:  1980-07       Impact factor: 2.953

9.  Contribution of Uptake and Efflux Transporters to Oral Pharmacokinetics of Furosemide.

Authors:  Revathi Chapa; Cindy Yanfei Li; Abdul Basit; Aarzoo Thakur; Mayur K Ladumor; Sheena Sharma; Saranjit Singh; Arzu Selen; Bhagwat Prasad
Journal:  ACS Omega       Date:  2020-12-15

10.  Clinical pharmacology of furosemide in neonates: a review.

Authors:  Gian Maria Pacifici
Journal:  Pharmaceuticals (Basel)       Date:  2013-09-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.